Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis
| Autor: | Yoshihide Asano, Yuta Norimatsu, Shinichi Sato, Jun Omatsu, Satoshi Toyama, Takuya Miyagawa, Ayumi Yoshizaki, Yusuke Watanabe, Yuki Fukui, Kentaro Awaji, Tetsuya Ikawa |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Arthritis Enzyme-Linked Immunosorbent Assay Inflammation Single Center Gastroenterology 03 medical and health sciences 0302 clinical medicine Rheumatology Internal medicine Arthropathy Humans Medicine Rheumatoid factor Stromal cell-derived factor 1 030212 general & internal medicine skin and connective tissue diseases Aged 030203 arthritis & rheumatology Scleroderma Systemic integumentary system biology business.industry Mesenchymal stem cell Middle Aged medicine.disease Connective tissue disease Chemokine CXCL12 biological factors Cross-Sectional Studies embryonic structures biology.protein Female Joint Diseases biological phenomena cell phenomena and immunity medicine.symptom business Biomarkers Follow-Up Studies |
| Zdroj: | International Journal of Rheumatic Diseases. 24:260-267 |
| ISSN: | 1756-185X 1756-1841 |
| DOI: | 10.1111/1756-185x.14037 |
| Popis: | AIM Systemic sclerosis (SSc) is an autoimmune connective tissue disease, in which extensive fibrotic change and vasculopathy affect the skin and various internal organs. It also involves the joints, causing stiffness, arthralgia, and arthritis. Although arthropathy is commonly observed in SSc, its underlying mechanism remains unknown. CXCL12, also known as stromal cell derived factor 1, is associated with inflammation, mesenchymal cell recruitment, angiogenesis, and collagen production, and is implicated in the development of various joint diseases. To assess the potential contribution of CXCL12 to SSc development, we investigated the clinical association of serum CXCL12 levels in patients with SSc. METHOD We conducted a cross-sectional analysis of 68 patients with SSc and 20 healthy controls recruited in a single center over 9 years. Serum CXCL12 levels were measured by enzyme-linked immunosorbent assay. RESULTS Serum CXCL12 levels were significantly higher in patients with SSc than in healthy controls (median 1554.0 pg/mL, 25th-75th centiles 1313.0-1914.0 pg/mL vs 967.4 pg/mL, 608.8-1271.0 pg/mL, P < 0.001). Patients with SSc with elevated CXCL12 levels had significantly more cases of arthropathy than those with normal CXCL12 levels (85.7% vs 25.0%, P = 0.01). Furthermore, patients with SSc with elevated CXCL12 levels showed an increased trend in the prevalence of limited range of motion of the finger joints compared with those with normal CXCL12 levels (60.0% vs 18.6%, P =0 .07). Moreover, serum CXCL12 levels were significantly correlated with the titers of rheumatoid factor in patients with SSc (r = .41, P = 0.001). CONCLUSION Elevated serum CXCL12 levels may be related to the development of SSc arthropathy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text